<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Most chromosomal translocations in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) involve oncogenes that are either up-regulated or form part of new chimeric genes </plain></SENT>
<SENT sid="1" pm="."><plain>The t(2;11)(p21;q23) translocation has been cloned in 19 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In addition to this, we have shown that this translocation is associated with a strong up-regulation of miR-125b (from 6- to 90-fold) </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro experiments revealed that miR-125b was able to interfere with primary human CD34(+) cell differentiation, and also inhibited terminal (monocytic and granulocytic) differentiation in HL60 and NB4 leukemic cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, miR-125b up-regulation may represent a new mechanism of myeloid cell transformation, and myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> carrying the t(2;11) translocation define a new clinicopathological entity </plain></SENT>
</text></document>